Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Return on Sales (2016 - 2025)

Historic Return on Sales for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to 0.86%.

  • China Pharma Holdings' Return on Sales rose 1500.0% to 0.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.79%, marking a year-over-year increase of 700.0%. This contributed to the annual value of 1.05% for FY2024, which is 6100.0% down from last year.
  • Per China Pharma Holdings' latest filing, its Return on Sales stood at 0.86% for Q3 2025, which was up 1500.0% from 0.52% recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' Return on Sales peaked at 0.24% during Q1 2023, and registered a low of 1.55% during Q2 2024.
  • In the last 5 years, China Pharma Holdings' Return on Sales had a median value of 0.54% in 2023 and averaged 0.61%.
  • As far as peak fluctuations go, China Pharma Holdings' Return on Sales crashed by -10100bps in 2024, and later soared by 10400bps in 2025.
  • Quarter analysis of 5 years shows China Pharma Holdings' Return on Sales stood at 0.34% in 2021, then dropped by -28bps to 0.43% in 2022, then crashed by -32bps to 0.57% in 2023, then tumbled by -88bps to 1.08% in 2024, then rose by 20bps to 0.86% in 2025.
  • Its last three reported values are 0.86% in Q3 2025, 0.52% for Q2 2025, and 0.69% during Q1 2025.